Creating biotechnologies that improve human health
We invent single-cell and cell-free genomics methods, then use them to understand how childhood cancers arise, evolve, and resist treatment, and to build faster, more accurate diagnostics.
What we will conquer together
Three things a lab can do that a company or a clinic alone cannot: invent the measurement, use it to find the answer, and carry it to the bedside.
Invent new ways to read single cells
The lab invented primary template-directed amplification (PTA), which recovers the genome of a single cell more completely and accurately than earlier methods, and has extended it to paired genome, transcriptome, and methylation readouts from the same cell.
Discover how cancer evolves and escapes
We follow individual leukemia cells through diagnosis, treatment, and relapse to learn why a small fraction of cells survive therapy, and how somatic mutations accumulate in normal tissues throughout life.
Translate discoveries into diagnostics
As a practicing pediatric oncologist, Chuck Gawad leads the lab toward tests that detect relapse and infection earlier, from plasma cell-free DNA sequencing to single-microbe genomics.
The projects that will make it happen
Four programs, each pairing a technology we build with a question it is built to answer. Together they take a single cell's genome from the bench to a child's bedside. Emerging directions include single-microbe genomics and circulating tumor cells.
Read about each program- 01→
Reading a whole cell at once
PTA and its extensions: genome, transcriptome, methylome, and surface proteome from the same single cell, plus methods for cell-free DNA.
- 02→
Outrunning relapse in childhood leukemia
Sequencing the rare leukemia cells that survive therapy, one at a time, to find the mutations behind resistance and to flag relapse months before it is clinically visible.
- 03→
Do common childhood viruses cause leukemia?
Testing whether respiratory viruses infect preleukemic B-cell precursors and, through interferon and APOBEC3A, write the mutations that turn a silent fusion into leukemia.
- 04→
When a disease lives in only some of a child's cells
Finding mutations that standard tests miss because they are present in only a fraction of cells, from childhood epilepsy and malformations to the first steps toward cancer.
Recent papers
-
Predicting bloodstream infection by plasma cell-free metagenomic sequencing: a prospective cohort study
-
Somatic mtDNA mutations at intermediate levels of heteroplasmy are a source of functional heterogeneity among primary leukemic cells
-
Single-Cell Sequencing Reveals Extensive Genetic Diversity Underlying Pediatric ALL Treatment Complexity
-
Defining heritability, plasticity, and transition dynamics of cellular phenotypes in somatic evolution
From the lab
Bill Evans becomes CEO of BioSkryb Genomics
William E. Evans, former President and CEO of St. Jude Children's Research Hospital and a long-time collaborator of the lab, is named Chief Executive Officer of BioSkryb Genomics, the company founded to bring PTA to researchers and clinics.
Cell-free DNA offers early warning for bloodstream infections in kids with leukemia
St. Jude announces results of a prospective study, with Chuck Gawad among the authors, showing that plasma microbial cell-free DNA sequencing can detect bloodstream infections in children with high-risk leukemia days before symptoms appear.
Mitochondrial DNA mutations shape how leukemia starts and progresses
A St. Jude release describes work with Veronica Gonzalez-Pena and Chuck Gawad showing that somatic mitochondrial DNA mutations at intermediate heteroplasmy are selected during leukemia development and may contribute to therapy resistance.
Our work is made possible by
Build the next generation of single-cell tools, steps from the patients they are for
The lab is growing and hiring now. We work in the Biomedical Innovations Building, a short walk from Lucile Packard Children's Hospital, Stanford's genomics cores, and the Chan Zuckerberg Biohub. Postdocs, scientists, analysts, students, and collaborators are all welcome.